Partial
Mostly Aligned
Patient Risk:
Medium
Summary
Partially aligned: IL-17A mechanism and the general live-vaccine avoidance concept are supported by the provided label excerpts. However, multiple vaccine-specific claims (adverse effects, IL-17A level increase) and several guideline attribution/timing details are not supported by the supplied labeling text.
Category Scores
Accurate Statements
Cosentyx works by targeting and blocking the action of interleukin-17A (IL-17A).
Label excerpt 12.1 states secukinumab selectively binds to IL-17A and inhibits its interaction with the IL-17 receptor.
Unsupported Statements
Cosentyx (secukinumab) is a biologic medication used to treat psoriasis, psoriatic arthritis, and ankylosing spondylitis.
Section 1 (Indications and Usage) is blank in the provided excerpts; no indication information is available to verify this claim.
Patients taking Cosentyx who received the live MMR vaccine experienced adverse effects including fever, rash, and fatigue.
The provided label excerpt 5.7 only provides general immunization guidance regarding live vaccines and does not describe MMR-specific outcomes or adverse effects.
Patients taking Cosentyx who received the live varicella (chickenpox) vaccine experienced a significant increase in IL-17A levels.
The provided excerpts include no vaccine-specific study findings and no claim about IL-17A level changes after live varicella vaccination.
The manufacturer of Cosentyx recommends that patients taking the medication avoid live vaccines for at least 4 weeks before and 4 weeks after receiving the vaccine.
Section 5.7 excerpt advises avoiding live vaccines in patients treated with COSENTYX, but it does not provide a '4 weeks before and 4 weeks after' timeframe.
The CDC recommends that patients taking biologic medications, including Cosentyx, avoid live vaccines for at least 4 weeks before and 4 weeks after receiving the vaccine.
No CDC guidance text is provided in the supplied label excerpts; only COSENTYX label excerpt 5.7 is available.
Contradictions
Low
AI Statement
Live vaccines may interact with Cosentyx, potentially leading to adverse effects.
Label Reference
5.7 (Immunizations) says COSENTYX may alter a patient's immune response to live vaccines and advises avoiding live vaccines in patients treated with COSENTYX.
Important Omissions
For vaccination timing (e.g., '4 weeks before and 4 weeks after'), the provided label excerpt does not include any specific interval.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
General avoidance of live vaccines is supported by label excerpt 5.7, but several specifics (MMR adverse effects, varicella IL-17A increase, and exact 4-week timing and CDC attribution) are unsupported by the provided labeling, which could lead to inaccurate counseling if acted upon.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Several claims are not supported by the provided COSENTYX label excerpts, especially vaccine-specific adverse events/biomarker changes and the exact '4 weeks before/after' timeframe.
Suggested Improvement
Limit statements to label-supported claims from the provided excerpts: IL-17A binding/inhibition (12.1) and general immunization guidance that COSENTYX may alter immune response to live vaccines and live vaccines should be avoided in patients treated with COSENTYX (5.7). Remove or verify vaccine-specific outcomes and exact timing with label sections not provided.